{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:05:51Z","timestamp":1792623951966,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jns.2021.117358","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T15:57:47Z","timestamp":1614095867000},"page":"117358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy"],"prefix":"10.1016","volume":"423","author":[{"given":"M.","family":"Garcia-Montojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Norato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.B.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Kiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vucic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mathers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.P.A.","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-L.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-J.","family":"Westeneng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.H.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Al-Chalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.117358_bb0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/1040841X.2018.1501345","article-title":"Human endogenous retrovirus-K (HML-2): a comprehensive review","volume":"44","author":"Garcia-Montojo","year":"2018","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.jns.2021.117358_bb0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/01.wnl.0000297552.13219.b4","article-title":"Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate","volume":"70","author":"McCormick","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117358_bb0015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1212\/01.WNL.0000150899.76130.71","article-title":"Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives","volume":"64","author":"Steele","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117358_bb0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1084\/jem.142.2.483","article-title":"RNA-instructed DNA polymerase activity in a cytoplasmic particulate fraction in brains from Guamanian patients","volume":"142","author":"Viola","year":"1975","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jns.2021.117358_bb0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/1096-9071(200008)61:4<527::AID-JMV17>3.0.CO;2-A","article-title":"Detection of reverse transcriptase activity in the serum of patients with motor neurone disease","volume":"61","author":"Andrews","year":"2000","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jns.2021.117358_bb0030","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/01.wnl.0000263188.77797.99","article-title":"A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS","volume":"68","author":"MacGowan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117358_bb0035","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.celrep.2019.09.066","article-title":"Postmortem cortex samples identify distinct molecular subtypes of ALS: Retrotransposon activation, oxidative stress, and activated glia","volume":"29","author":"Tam","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.jns.2021.117358_bb0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13024-018-0275-3","article-title":"Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins","volume":"13","author":"Mayer","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jns.2021.117358_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40478-019-0698-2","article-title":"Quantitative analysis of human endogenous retrovirus-K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV-K RNA in amyotrophic lateral sclerosis","volume":"7","author":"Garson","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.jns.2021.117358_bb0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ana.22149","article-title":"Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis","volume":"69","author":"Douville","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2021.117358_bb0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40478-019-0753-z","article-title":"Technical considerations in detection of HERV-K in amyotrophic lateral sclerosis: selection of controls and the perils of qPCR","volume":"7","author":"Garcia-Montojo","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.jns.2021.117358_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac8201","article-title":"Human endogenous retrovirus-K contributes to motor neuron disease","volume":"7","author":"Li","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jns.2021.117358_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071584","article-title":"Pro-inflammatory signaling upregulates a neurotoxic conotoxin-like protein encrypted within human endogenous retrovirus-K","volume":"9","author":"Curzio","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jns.2021.117358_bb0070","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/ene.13648","article-title":"Humoral immunity response to human endogenous retroviruses K\/W differentiates between amyotrophic lateral sclerosis and other neurological diseases","volume":"25","author":"Arru","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2021.117358_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12977-017-0347-4","article-title":"Inhibition of human endogenous retrovirus-K by antiretroviral drugs","volume":"14","author":"Tyagi","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.jns.2021.117358_bb0080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/21678421.2019.1632899","article-title":"Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the lighthouse trial","volume":"20","author":"Gold","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.jns.2021.117358_bb0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/21678421.2015.1049183","article-title":"A revision of the El Escorial criteria - 2015","volume":"16","author":"Ludolph","year":"2015","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.jns.2021.117358_bb0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1874613601509010112","article-title":"Further evidence that human endogenous retrovirus K102 is a replication competent foamy virus that may antagonize HIV-1 replication","volume":"9","author":"Laderoute","year":"2015","journal-title":"Open AIDS J"},{"key":"10.1016\/j.jns.2021.117358_bb0095","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1097\/QAD.0b013e3282f14d64","article-title":"The replicative activity of human endogenous retrovirus K102 (HERV-K102) with HIV viremia","volume":"21","author":"Laderoute","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jns.2021.117358_bb0100","doi-asserted-by":"crossref","first-page":"9673","DOI":"10.1128\/JVI.01147-14","article-title":"Genomic flexibility of human endogenous retrovirus type K","volume":"88","author":"Dube","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.jns.2021.117358_bb0105","doi-asserted-by":"crossref","first-page":"e01309-17","DOI":"10.1128\/JVI.01309-17","article-title":"Susceptibility of human endogenous retrovirus type-K to reverse transcriptase inhibitors","volume":"91","author":"Contreras-Galindo","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.jns.2021.117358_bb0110","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/jpet.103.053827","article-title":"Effect of transport inhibitors and additional anti-HIV drugs on the movement of lamivudine (3TC) across the Guinea pig brain barriers","volume":"306","author":"Gibbs","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jns.2021.117358_bb0115","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1128\/AAC.49.6.2504-2506.2005","article-title":"Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid","volume":"49","author":"Capparelli","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jns.2021.117358_bb0120","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1212\/01.WNL.0000156913.24701.72","article-title":"A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS","volume":"64","author":"Scelsa","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117358_bb0125","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00001756-199306000-00056","article-title":"Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis","volume":"4","author":"Westarp","year":"1993","journal-title":"Neuroreport"},{"key":"10.1016\/j.jns.2021.117358_bb0130","first-page":"504","article-title":"Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients","volume":"13","author":"Garcia-Montojo","year":"2007","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jns.2021.117358_bb0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2377-12-107","article-title":"MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up","volume":"12","author":"Dominguez-Mozo","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2021.117358_bb0140","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1128\/JVI.80.7.3438-3444.2006","article-title":"Effects of type I interferons on friend retrovirus infection","volume":"80","author":"Gerlach","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.jns.2021.117358_bb0145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1212\/WNL.54.2.469","article-title":"A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian amyotrophic lateral sclerosis study group","volume":"54","author":"Beghi","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117358_bb0150","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/WNL.0000000000003258","article-title":"HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy","volume":"87","author":"Bowen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117358_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082911","article-title":"A beta 1-42 and tau as potential biomarkers for diagnosis and prognosis of amyotrophic lateral sclerosis","volume":"21","author":"Lanznaster","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2021.117358_bb0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide Tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:54:27Z","timestamp":1758383667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":32,"alternative-id":["S0022510X21000514"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117358","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117358"}}